Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR through APMAP

Cholesterol increases the risk of aggressive prostate cancer and has emerged as a potential therapeutic target for prostate cancer. The functional roles of cholesterol in prostate cancer metastasis are not fully understood. Here, we found that cholesterol induces the epithelial-to-mesenchymal transi...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 79; no. 12; pp. 3063 - 3075
Main Authors Jiang, Siyuan, Wang, Xuetong, Song, Dalong, Liu, XiaoJun, Gu, Yinmin, Xu, Zhiyuan, Wang, Xiaodong, Zhang, Xiaolu, Ye, Qinong, Tong, Zhou, Yan, BingXue, Yu, Jie, Chen, Yunzhao, Sun, Minxuan, Wang, Yang, Gao, Shan
Format Journal Article
LanguageEnglish
Published United States 15.06.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cholesterol increases the risk of aggressive prostate cancer and has emerged as a potential therapeutic target for prostate cancer. The functional roles of cholesterol in prostate cancer metastasis are not fully understood. Here, we found that cholesterol induces the epithelial-to-mesenchymal transition (EMT) through extracellular-regulated protein kinases 1/2 pathway activation, which is mediated by EGFR and adipocyte plasma membrane-associated protein (APMAP) accumulation in cholesterol-induced lipid rafts. Mechanistically, APMAP increases the interaction with EGFR substrate 15-related protein (EPS15R) to inhibit the endocytosis of EGFR by cholesterol, thus promoting cholesterol-induced EMT. Both the mRNA and protein levels of APMAP are upregulated in clinical prostate cancer samples. Together, these findings shed light onto an APMAP/EPS15R/EGFR axis that mediates cholesterol-induced EMT of prostate cancer cells. SIGNIFICANCE: This study delineates the molecular mechanisms by which cholesterol increases prostate cancer progression and demonstrates that the binding of cholesterol-induced APMAP with EPS15R inhibits EGFR internalization and activates ERK1/2 to promote EMT. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/12/3063/F1.large.jpg.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0008-5472
1538-7445
1538-7445
DOI:10.1158/0008-5472.CAN-18-3295